Recombinant SP-A and SP-D may also have potential as novel adjunctive synthetic anti-inflammatory and anti-infective agents in other disease settings including severe asthma and COPD (Clark, 2010, Mackay et al., 2016). Here, SFTPA2 is linked to asthma.